524937-17-5

Basic information

• Product Name: 3-Cl-AHPC
• Synonyms: 3-Cl-AHPC
• CAS NO: 524937-17-5
• Molecular Weight: 408.925
• Mol File: 524937-17-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-Cl-AHPC(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Cl-AHPC(524937-17-5)
• EPA Substance Registry System: 3-Cl-AHPC(524937-17-5)

Safety Data

• Hazardous Substances Data: 524937-17-5(Hazardous Substances Data)

Upstream product

• 862651-04-5 methyl E-3-[3’-(adamantan-1-yl)-2-chloro-4’-hydroxybiphenyl-4-yl]acrylate 
• 185527-66-6 methyl E-(3-chloro-4-hydroxyphenyl)acrylate 
• 862651-06-7 methyl E-3-(3-chloro-4-trifluoromethanesulfonyloxyphenyl)acrylate 

Relevant articles and documents

Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors

To investigate the influence of the adamantyl group on the biological properties of known HDAC inhibitors with a 4-phenylcinnamic skeleton, a series of compounds having the adamantyl moiety in the cap structure were synthesized and compared to the corresponding hydroxamic acids lacking this group. An unexpected finding was the substantial reduction of inhibitory activity toward the tested enzymes, in particular HDAC6, following the introduction of the adamantyl group. In spite of the reduced ability to function as HDAC inhibitors, the compounds containing the adamantyl moiety still retained a good efficacy as antiproliferative and proapoptotic agents. A selected compound (2c; ST3056) of this series exhibited an appreciable antitumor activity against the colon carcinoma xenograft HCT116.

Induction of apoptosis in cancer cells

The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.